

Id	Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
54196	12/YH/0231	206207-025 CONSTANCE - Post Authorisation Safety Study of OZURDEX (Dexamethasone Intravitreal Implant): A Prospective Observational Study to Evaluate Long-Term Safety in Real-World Clinical Practice	Available	40	Available	15/04/2014	Closed - In Follow Up	Y	42 patients recruited
54197	12/EE/0176	Randomised, phase IV, placebo-controlled, comparative study to evaluate the efficacy and safety of tapering methotrexate (MTX) dosage versus maintaining the dosage in patients with severe active Rheumatoid Arthritis (RA) who have demonstrated an inadequate response to prior disease-modifying anti-rheumatic drugs (DMARDs) treatment and have initiated RoActemra? (Toilizumab, TCZ) in combination with MTX. CCRN 731	Available	8	Available	31/12/2015	Closed - In Follow Up	N	Start of study delayed due to issue with pharmacy. Sponsor closed trial early - study was 86.29%TTT with recruitment end date of 31/12/2015.
54198	12/WM/0341	Amgen Protocol 20110118: A Double-blind, Randomised, Placebo-controlled, Multicentre Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when AMG145 is used in Combination with Statin Therapy in Patients with Clinically Evident Cardiovascular Disease	Available	30	Available	01/04/2015	Closed - In Follow Up	N/A	17 patients recruited to date and the Sponsor closed the study early
54199	12/NW/0739	A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphines-induced Photochemical Internalisation (PCI) of Gemcitabine following by Gemcitabine/Cisplatin Chemotherapy in Patients with Locally Advanced Inoperable Cholangiocarcinomas	Available	5	No Date Agreed With Sponsor		Open	N/A	1 patient recruited. Early Phase rare cancer study
54200	13/SC/0010	A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 28 Day Oral Administration of BAY 85-8501 in Patients With Bronchiectasis	Available	5	Available	10/04/2014	Closed - Follow Up Complete	Y	
54201	13/LO/0219	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) GILEAD	Available	4	Available	01/10/2015	Open	Y	
54202	12/LO/1950	A Randomised, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin	Available	5	Available	27/11/2019	Open	N/A	
54203	13/NW/0189	Global, Prospective, Multi-Center, Non-randomized, Controlled Non-inferiority Trial to Evaluate Symptom Relief in Patients with Medial Knee Osteoarthritis (OA) Treated with the KineSpring? Knee Implant for Load Reduction Compared to High Tibial Osteotomy (HTO).	Available	15	Available	30/06/2015	Open	Y	target of 15 met early
54204	14/LO/1461	A multi-center, double-blind, randomized, placebo-controlled, parallel group, exploratory Phase 2 study to assess efficacy and safety of seleqipag in adult subjects with Raynaud's Phenomenon secondary to Systemic Sclerosis	Available	5	Available	01/08/2015	Closed - Follow Up Complete	Y	6 patients recruited from site
54205	13/EE/0231	Nacetylcysteine in Idiopathic Pulmonary Fibrosis.1	Available	4	Available	13/06/2014	Closed - Follow Up Complete	Y	
54206	13/LO/1321	A PHASE II, RANDOMIZED, DOUBLEBLIND, PLACEBO CONTROLLED, STUDY TO ASSESS THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS	Available	4	Available	01/04/2016	Open	Y	Met target early
54207	13/EM/0348	Safety and Efficacy assessment of Monoprost (unpreservedlatanoprost) in comparison with Lumigan 0.01% and Lumigan 0.03% UD, in patients with primary open angle glaucoma or ocular hypertension, stabilized by Lumigan 0.01% with ocular surface intolerance	Available	10	Available	31/03/2016	Open	Y	Trial date extended with Sponsor.
54208	13/LO/1517	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of FG-4592 in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis	Available	5	Available	15/07/2017	Open	N/A	
54209	13/EM/0251	A multicenter, randomized, double-blind, placebo controlled phase III study to evaluate the efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failure patients	Available	20	Available	23/06/2016	Open	N/A	
54210	14/NW/0352	PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF)INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS	Available	4	Available	31/08/2017	Open	N/A	
54211	13/EM/0423	A randomised, double blind, placebo controlled, parallel group, dose ranging study of GWP42004 as add on to metformin in the treatment of participants with Type 2 diabetes	Available	4	Available	30/09/2015	Open	Y	Sponsor placed study on hold to recruitment from August 2014 to January 2015.
54212	13/LO/1557	CALM-NET: A Phase IV, Multicentre, Open label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients receiving Deep Subcutaneous Administrations of lanreotide Autogel? to treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)	Available	4	Available	19/01/2016	Open	N/A	
54213	14/EE/0102	A prospective, randomized, open-label, blinded endpoint evaluation (PROBE) parallel group study comparing edoxaban (DU-176b) with enoxaparin/warfarin followed by warfarin alone in subjects undergoing planned electrical cardioversion of nonvalvular atrial fibrillation	Available	9	Available	02/10/2015	Open	N/A	
54214	14/SC/0065	A Randomized, Multicenter, DoubleBlind, Parallel, PlaceboControlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus	Available	8	Available	30/06/2015	Closed - In Follow Up	Y	
54215	13/SC/0616	A Phase II, randomised, observerblind, placebocontrolled, multicentre study to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' investigational vaccine GSK2838504A, when administered intramuscularly according to a 0, 2 month schedule to COPD patients aged 40 to 80 years	Available	10	Available	01/07/2016	Open	N/A	
54216	14/EM/1070	A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety and Efficacy of Icalitbant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults	Available	5	Available	01/06/2016	Suspended	N/A	
54217	14/LO/1443	A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis	Available	5	Available	01/08/2018	Open	N/A	
54218	14/NE/1103	A phase 3 randomized double blind study of tofacitinib with and without methotrexate in comparison to adalimumab with methotrexate in subjects with moderately to severely active rheumatoid arthritis.	Available	2	Available	15/12/2016	Open	N/A	
54219	14/EE/1001	A 6-MONTH, PROSPECTIVE, RANDOMIZED, MULTICENTER, PLACEBO-CONTROLLED SAFETY STUDY OF OTO-104 GIVEN AT 3-MONTH INTERVALS BY INTRATYMPANIC INJECTION IN SUBJECTS WITH UNILATERAL MENIERE'S DISEASE FOLLOWED BY A 6-MONTH OPEN-LABEL EXTENSION	Available	6	No Date Agreed With Sponsor		Closed - In Follow Up	N/A	3 patients recruited. sponsor closed trial as global recruitment met.
54220	14/LO/2037	A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Available	2	Available	15/09/2016	Open	N/A	
54221	14/NE/1169	Phase IV Trial Assessing the Impact of Residual Inflammation Detected via Imaging Techniques, Drug Levels and Patient Characteristics on the Outcome of Dose Tapering of Adalimumab in Clinical Remission Rheumatoid Arthritis (RA) Subjects (PREDICTRA)	Available	4	Available	29/08/2017	Open	N/A	54221